In vivo and vitro experiments show that long noncoding RNA treatment alleviates pathological cardiac hypertrophy
In a recent study, the regulatory role of the long noncoding RNA (lncRNA) Gm20257 in pathological cardiac hypertrophy has ...
News Medical on MSN9d
Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma
In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...
Impacts16h
Ivermectin for Cancer in Humans: Understanding the Dosage and Potential Benefits
Ivermectin is an antiparasitic agent, and its potential as an anticancer agent has recently attracted increasing attention.
EurekAlert!11d
Berry-flavored may be more dangerous than non-flavored vapes: study
Berry-flavored vapes can weaken the lungs’ natural defenses, making it harder for the body to fight off infections, new ...
DutchNews.NL15d
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
Collaboration goal to develop alternative methods to assess clinical performance of product variants under different ...
How does the brain keep calm? Insight into brain stability and the key role of NMDA receptors
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional ...
Medscape4d
Chicken Soup Inhibits Neutrophil Chemotaxis In Vitro
The observations that activities are present in the clarified ... of neutrophil chemotaxis by chicken soup in vitro. This was not an in vivo clinical trial. Whether clinical benefits would be ...
Business Insider2d
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt ...